Baseline characteristics and feasibility of clinical outcome measures in <scp>CDKL5</scp> deficiency disorder: The <scp>CANDID</scp> observational study
The scales in the CANDID study capture disease-related deficits and phenotype variability in CDD. Floor effects in subdomains aligned with disease severity. The GMFM-88 lacks granularity, and its operational limitations make it unsuitable for CDD trials. Baseline analyses demonstrate the feasibility and potential value of most selected scales, supporting their use in optimizing trial design and endpoint selection for future CDD clinical trials.
Authors
- Tricia Cimms
- Kristina Lindsten
- Alison Skrinar (ORCID: https://orcid.org/0000-0002-6538-0644)
- Xavier Liogier D’ardhuy
- Marco Rizzo (ORCID: https://orcid.org/0000-0002-1805-3536)
- Orrin Devinsky
- Ana Mingorance
- Peter St. Wecker
- CANDID Partners
Institutions
- Biogen (United States) (US)
- North Carolina Institute of Medicine (US)
- Ultragenyx Pharmaceutical (United States) (US)
- Redwood Pharma (Sweden) (SE)
- Loulou Foundation (GB)
- New York University (US)
Publication Details
- Journal
- Epilepsia
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1002/epi.70095
- Primary Topic
- Genetics and Neurodevelopmental Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00